Schizophyllan
Based on 1 Customer Validation
Schizophyllan (SPG) is an orally active extracellular β-glucan produced by the fungus Schizophyllum commune. Schizophyllan improves mitochondrial function and protects against metabolic liver injury by activating the SIRT3 pathway. Schizophyllan inhibits osteoclastogenesis and promotes osteoblast differentiation by suppressing the phosphorylation of JNK/p38, as well as downregulating PGC1β/PPARγ, c-Fos and NFATc1. Recognized via Dectin-1, schizophyllan enables precise delivery of oligonucleotide drugs and antigens to antigen-presenting cells, thus holding great potential in the treatment of inflammatory diseases and vaccine development.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 9050-67-3
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Biological Activity
|
Dectin-1 |
Schizophyllan (5-200 μg/mL; 4-7 h) dose-dependently inhibits RANKL-induced osteoclast differentiation, TRAP activity, F-actin ring formation, and bone resorption in mouse bone marrow-derived macrophages. At the concentration of 200 μg/mL, it reduces the number of mature osteoclasts by approximately 95% and almost completely blocks bone resorption[1].
Schizophyllan (200 μg/mL; 0-4 d) downregulates the expression of RANKL-induced osteoclast differentiation marker genes, and inhibits key signaling pathways (JNK/p38 MAPK, PGC1β/PPARγ) and transcription factors (c-Fos, NFATc1) during osteoclastogenesis in mouse bone marrow-derived macrophages[1].
Schizophyllan (50-200 μg/mL; 1-6 d) dose-dependently inhibits osteoclast formation in a co-culture system of mouse bone marrow mononuclear cells and osteoblasts, and downregulates the expression of osteoclastogenic factors *Csf1* and *Tnfsf11* in mouse calvarial osteoblasts at the concentration of 200 μg/mL[1].
Schizophyllan (200 μg/mL; 7-24 d) slightly enhances mineralized nodule formation in mouse calvarial osteoblasts and upregulates the expression of osteoblast differentiation marker genes and transcription factors[1].
Schizophyllan (30 μg/mL) specifically binds to soluble recombinant mouse Dectin-1 protein, among which dA60 (S)/SPG exhibits the strongest binding activity[2].
Schizophyllan specifically hybridizes with target TNF-α sense RNA in vitro and does not dissociate from SPG[2].
Schizophyllan delivers the OVA257-264 peptide to murine peritoneal macrophages, and its antigen-presenting efficacy is comparable to that of the free conjugate[2].
Schizophyllan (0-24 h) is preferentially taken up by mouse RAW264 macrophages, and the uptake amount increases continuously within 24 h[2].
Schizophyllan (100 μg/mL; 1-2 d) regulates the acetylation level and expression of SOD2 in primary hepatocytes from SOD2−/− mice, and reduces mitochondrial ROS production in primary hepatocytes from wild-type mice in a SIRT3-dependent manner[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Schizophyllan (100 mg/kg; p.o.; daily; 4-8 weeks) induces SIRT3 expression in mouse liver and adipose tissue, activates SOD2 via deacetylation, and improves hepatic mitochondrial function in a SIRT3-dependent manner[3].
Schizophyllan (100 mg/kg; p.o.; daily; 4-8 weeks) induces SIRT3-dependent deacetylation and activation of SDHA in mouse brown adipose tissue[3].
Schizophyllan (100 mg/kg; p.o.; daily; 6 weeks) reduces chronic ethanol-induced liver damage in wild-type mice via activation of the SIRT3-SOD2 pathway, restoring liver function and morphology[3].
Schizophyllan (100 mg/kg; p.o.; daily; 20 weeks) reduces CLA-induced metabolic adverse effects in wild-type mice via activation of the SIRT3-SDHA pathway, restoring tissue weights and serum chemistry markers[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice (5-week-old, male)[1]
-
Dosage:25 mg/mouse
-
Administration:s.c.; daily; 9 days
-
Result:Reduced TRAP-positive osteoclast area to ~60% relative to LPS-only group (~100%).
Decreased eroded surface per bone surface (ES/BS) from ~30% to ~25% relative to LPS-only group.
Lowered osteoclast counts from ~28 to ~18 per field relative to LPS-only group.
Did not significantly alter TRAP-positive area, ES/BS, or osteoclast counts relative to PBS controls when administered alone.
-
Animal Model:C57BL/6J; SIRT3−/− (B6.129S6(Cg)Sirt3tm1.1Fwa/J); SOD2−/− (B6.129S7-Sod2tm1Leb/J) (female, 6 weeks old)[3]
-
Dosage:100 mg/kg
-
Administration:p.o.; daily; 4 to 8 weeks
-
Result:Markedly induced SIRT3 expression in liver and brown adipose tissue, with peak mRNA and protein expression at 4-6 weeks.
Reduced SOD2 acetylation (K68 and K122 sites) in liver of wild-type mice.
Increased SOD2 enzyme activity to ~5 relative units/mg protein by 8 weeks in wild-type mice.
Increased hepatic oxygen consumption rate (including basal respiration and maximal respiratory capacity) in wild-type mice.
Reduced mitochondrial ROS production in wild-type mice.
Abrogated all above effects in SIRT3−/− mice.
-
Animal Model:C57BL/6J; SIRT3−/− (B6.129S6(Cg)Sirt3tm1.1Fwa/J); SDHA−/− (B6N(Cg)-Sdhatm2b(KOMP)Wtsi/2J) (female, 6 weeks old)[3]
-
Dosage:100 mg/kg
-
Administration:p.o.; daily; 4 to 8 weeks
-
Result:Reduced SDHA acetylation in brown adipose tissue of wild-type mice.
Increased SDHA enzyme activity to ~5 relative units/mg protein by 8 weeks in wild-type mice.
Abrogated all above effects in SIRT3−/− and SDHA−/− mice.
-
Animal Model:C57BL/6J; SIRT3−/− (B6.129S6(Cg)Sirt3tm1.1Fwa/J) (female, 6 weeks old, alcohol-induced liver damage model)[3]
-
Dosage:100 mg/kg
-
Administration:p.o.; daily; 6 weeks
-
Result:Reduced SOD2 acetylation in liver of wild-type mice.
Increased SOD2 enzyme activity in wild-type mice.
Reduced mitochondrial ROS production in wild-type mice.
Reduced blood acetaldehyde and ethanol levels in wild-type mice.
Restored final body weight to 21.94 g in wild-type mice.
Restored liver weight to 0.86 g in wild-type mice.
Reduced histologic liver damage in wild-type mice.
Abrogated all above protective effects in SIRT3−/− mice.
-
Animal Model:C57BL/6J; SIRT3−/− (B6.129S6(Cg)Sirt3tm1.1Fwa/J); SDHA−/− (B6N(Cg)-Sdhatm2b(KOMP)Wtsi/2J) (female, 6 weeks old)[3]
-
Dosage:20 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 20 weeks
-
Result:Reduced SDHA acetylation in brown adipose tissue of wild-type mice at 100 mg/kg.
Increased SDHA enzyme activity in wild-type mice at 100 mg/kg.
Abrogated all above protective effects in SIRT3−/− and SDHA−/− mice.
Chemical Information
-
CAS No. 9050-67-3
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Schizophyllan]
-
Synonyms
SPG
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
H2O : 1.82 mg/mL (ultrasonic and warming and adjust pH to 12 with 1 M NaOH and heat to 60°C)
순도&문서
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kim SH, et al. The effect of Schizophyllan on the differentiation of osteoclasts and osteoblasts. Biochem Biophys Res Commun. 2024;710:149860. [Content Brief]
[2]. Mochizuki S, et al. Oligonucleotide delivery to antigen presenting cells by using schizophyllan. Drug Metab Pharmacokinet. 2022;42:100434. [Content Brief]
[3]. Lee D, et al. Dietary schizophyllan reduces mitochondrial damage by activating SIRT3 in mice. Arch Pharm Res. 2020;43(4):449-461. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Schizophyllan Related Classifications
HY-165126 Related Classifications
Powered by Bioz